Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Wang CS, Kavalali ET, Monteggia LM
requires -20C for long-term storage Intended Use: In vitro laboratory research and animal studies only
Market Players, Key Developments, and Competitive Intelligence To learn more about this report, Key Developments On June 30, 2025, Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on peptide-based therapeutics, announced the nomination of PN-477, a triple agonist peptide targeting GLP-1, GIP, and GCG receptors, for obesity treatment
They do not replace thyroid hormone GLP-1 medications do not improve thyroid hormone production
Mimo obiecujcych wynikw bada, stosowanie peptydu BPC 157 budzi pewne kontrowersje , poniewa nie zosta on jeszcze zatwierdzony przez FDA do uytku klinicznego
US$ 24.92
US$ 29.80
US$ 25.84
US$ 28.00
